Evidence map›Paper›PMID 25117081›Full record

SynthesisPLoS medicine2014

Heart failure care in low- and middle-income countries: a systematic review and meta-analysis.

Thomas Callender, Mark Woodward, Gregory Roth, Farshad Farzadfar, Jean-Christophe Lemarie, Stéphanie Gicquel, John Atherton, Shadi Rahimzadeh, Mehdi Ghaziani, Maaz Shaikh and 20 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 8 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 8 syntheses or guidelines pooled it, 279 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 16 institutions in 12 countries.

Thomas CallenderThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Mark WoodwardThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom; The George Institute for Global Health, University of Sydney, Sydney, Australia.
Gregory RothInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Farshad FarzadfarNon-Communicable Diseases Research Centre, Tehran University of Medical Sciences, Tehran, Iran; Endocrinology and Metabolism Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Jean-Christophe LemarieEffi-Stat, Paris, France.
Stéphanie GicquelEffi-Stat, Paris, France.
John AthertonDepartment of Cardiology, Royal Brisbane and Women's Children Hospital and University of Queensland School of Medicine, Brisbane, Australia.
Shadi RahimzadehNon-Communicable Diseases Research Centre, Tehran University of Medical Sciences, Tehran, Iran; Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehdi GhazianiNon-Communicable Diseases Research Centre, Tehran University of Medical Sciences, Tehran, Iran; Endocrinology and Metabolism Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Maaz ShaikhThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom; The George Institute for Global Health, Hyderabad, India.
Derrick BennettClinical Trials Service Unit, University of Oxford, Oxford, United Kingdom.
Anushka PatelThe George Institute for Global Health, University of Sydney, Sydney, Australia.
Carolyn S P LamNational University of Singapore, Singapore.
Karen SliwaHatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa.
Antonio BarrettoFaculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Bambang Budi SiswantoNational Cardiovascular Centre University Indonesia, Jakarta, Indonesia.
Alejandro DiazUniversidad Nacional del Centro de la Provincia de Buenos Aires, Buenos Aires, Argentina.
Daniel HerpinCentre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France.
Henry KrumCentre of Cardiovascular Research & Education in Therapeutics, Monash University, Melbourne, Australia.
Thomas EliaszThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Anna ForbesThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Alastair KiszelyThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Rajit KhoslaThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Tatjana PetrinicBodleian Healthcare Libraries, University of Oxford, Oxford, United Kingdom.
Devarsetty PraveenThe George Institute for Global Health, University of Sydney, Sydney, Australia; The George Institute for Global Health, Hyderabad, India.
Roohi ShrivastavaThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Du XinThe George Institute for Global Health, Peking University, Beijing, China.
Stephen MacMahonThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom; The George Institute for Global Health, University of Sydney, Sydney, Australia.
John McMurrayUniversity of Glasgow, Glasgow, United Kingdom.
Kazem RahimiThe George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
University of Oxford · GBTehran University of Medical Sciences · IRUniversity of Sydney · AUCentre Hospitalier Universitaire de Poitiers · FRGeorge Institute for Global Health · GBHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRMonash University · AUNational Brain Centre · IDNational University of Singapore · SGPeking University · CNThe George Institute for Global Health · AUUniversidad Nacional del Centro de la Provincia de Buenos Aires · ARUniversity of Cape Town · ZAUniversity of Glasgow · GBUniversity of Queensland · AUUniversity of Washington · US

Funding

Department of Health CDF-2013-06-012
6 · The paper itself

Abstract

backgroundHeart failure places a significant burden on patients and health systems in high-income countries. However, information about its burden in low- and middle-income countries (LMICs) is scant. We thus set out to review both published and unpublished information on the presentation, causes, management, and outcomes of heart failure in LMICs. METHODS AND

findingsMedline, Embase, Global Health Database, and World Health Organization regional databases were searched for studies from LMICs published between 1 January 1995 and 30 March 2014. Additional unpublished data were requested from investigators and international heart failure experts. We identified 42 studies that provided relevant information on acute hospital care (25 LMICs; 232,550 patients) and 11 studies on the management of chronic heart failure in primary care or outpatient settings (14 LMICs; 5,358 patients). The mean age of patients studied ranged from 42 y in Cameroon and Ghana to 75 y in Argentina, and mean age in studies largely correlated with the human development index of the country in which they were conducted (r = 0.71, p<0.001). Overall, ischaemic heart disease was the main reported cause of heart failure in all regions except Africa and the Americas, where hypertension was predominant. Taking both those managed acutely in hospital and those in non-acute outpatient or community settings together, 57% (95% confidence interval [CI]: 49%-64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 28%-41%) with beta-blockers, and 32% (95% CI: 25%-39%) with mineralocorticoid receptor antagonists. Mean inpatient stay was 10 d, ranging from 3 d in India to 23 d in China. Acute heart failure accounted for 2.2% (range: 0.3%-7.7%) of total hospital admissions, and mean in-hospital mortality was 8% (95% CI: 6%-10%). There was substantial variation between studies (p<0.001 across all variables), and most data were from urban tertiary referral centres. Only one population-based study assessing incidence and/or prevalence of heart failure was identified.

conclusionsThe presentation, underlying causes, management, and outcomes of heart failure vary substantially across LMICs. On average, the use of evidence-based medications tends to be suboptimal. Better strategies for heart failure surveillance and management in LMICs are needed. Please see later in the article for the Editors' Summary.

Indexed as

Developing CountriesHeart FailureHumans

Identifiers

PMID25117081
PMCPMC4130667
OpenAlexW1977483151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.